Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens

Incidence, risk factors, and possible role of antithrombin

Michelle A. Elliott, Robert C. Wolf, Christopher C. Hook, Rajiv K. Pruthi, John A. Heit, Louis L. Letendre, Ayalew Tefferi, Scott H Kaufmann, Ruben A. Mesa, Mark R Litzow

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Thromboembolism (TE) is a known complication of L-asparaginase (ASP) therapy of acute lymphoblastic leukemia (ALL), possibly attributable to reduced synthesis of natural anticoagulants, in particular antithrombin (AT). This retrospective single institution study was performed to determine the TE incidence among adults undergoing induction with contemporary, ASP-containing regimens. Ten of 54 (18.5%) consecutive adults developed symptomatic, objectively confirmed TE, at a median of 5.5 days after the first ASP dose. These were notable for CNS and upper extremity localization, varied significantly according to ALL immunophenotype (precursor B: 11% vs. T cell: 33%), without apparent effect of schedule or total dose of ASP. Median baseline AT level was 94% and fell to a nadir of 47% (P < 0.0001) during ASP therapy. Prophylactic AT had been given to 17 during ASP therapy. None of these developed TE vs. 10/37 (27%) without replacement (P = 0.021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions.

Original languageEnglish (US)
Pages (from-to)1545-1551
Number of pages7
JournalLeukemia and Lymphoma
Volume45
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

Asparaginase
Antithrombins
Thromboembolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Incidence
Therapeutics
Upper Extremity
Anticoagulants
Appointments and Schedules
T-Lymphocytes
Population

Keywords

  • Acute lymphoblastic leukemia
  • Antithrombin
  • L-asparaginase
  • Thromboembolism

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens : Incidence, risk factors, and possible role of antithrombin. / Elliott, Michelle A.; Wolf, Robert C.; Hook, Christopher C.; Pruthi, Rajiv K.; Heit, John A.; Letendre, Louis L.; Tefferi, Ayalew; Kaufmann, Scott H; Mesa, Ruben A.; Litzow, Mark R.

In: Leukemia and Lymphoma, Vol. 45, No. 8, 08.2004, p. 1545-1551.

Research output: Contribution to journalArticle

Elliott, Michelle A. ; Wolf, Robert C. ; Hook, Christopher C. ; Pruthi, Rajiv K. ; Heit, John A. ; Letendre, Louis L. ; Tefferi, Ayalew ; Kaufmann, Scott H ; Mesa, Ruben A. ; Litzow, Mark R. / Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens : Incidence, risk factors, and possible role of antithrombin. In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 8. pp. 1545-1551.
@article{afcdb19a210245f3a637391c2db20ae1,
title = "Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin",
abstract = "Thromboembolism (TE) is a known complication of L-asparaginase (ASP) therapy of acute lymphoblastic leukemia (ALL), possibly attributable to reduced synthesis of natural anticoagulants, in particular antithrombin (AT). This retrospective single institution study was performed to determine the TE incidence among adults undergoing induction with contemporary, ASP-containing regimens. Ten of 54 (18.5{\%}) consecutive adults developed symptomatic, objectively confirmed TE, at a median of 5.5 days after the first ASP dose. These were notable for CNS and upper extremity localization, varied significantly according to ALL immunophenotype (precursor B: 11{\%} vs. T cell: 33{\%}), without apparent effect of schedule or total dose of ASP. Median baseline AT level was 94{\%} and fell to a nadir of 47{\%} (P < 0.0001) during ASP therapy. Prophylactic AT had been given to 17 during ASP therapy. None of these developed TE vs. 10/37 (27{\%}) without replacement (P = 0.021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions.",
keywords = "Acute lymphoblastic leukemia, Antithrombin, L-asparaginase, Thromboembolism",
author = "Elliott, {Michelle A.} and Wolf, {Robert C.} and Hook, {Christopher C.} and Pruthi, {Rajiv K.} and Heit, {John A.} and Letendre, {Louis L.} and Ayalew Tefferi and Kaufmann, {Scott H} and Mesa, {Ruben A.} and Litzow, {Mark R}",
year = "2004",
month = "8",
doi = "10.1080/10428190410001693588",
language = "English (US)",
volume = "45",
pages = "1545--1551",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens

T2 - Incidence, risk factors, and possible role of antithrombin

AU - Elliott, Michelle A.

AU - Wolf, Robert C.

AU - Hook, Christopher C.

AU - Pruthi, Rajiv K.

AU - Heit, John A.

AU - Letendre, Louis L.

AU - Tefferi, Ayalew

AU - Kaufmann, Scott H

AU - Mesa, Ruben A.

AU - Litzow, Mark R

PY - 2004/8

Y1 - 2004/8

N2 - Thromboembolism (TE) is a known complication of L-asparaginase (ASP) therapy of acute lymphoblastic leukemia (ALL), possibly attributable to reduced synthesis of natural anticoagulants, in particular antithrombin (AT). This retrospective single institution study was performed to determine the TE incidence among adults undergoing induction with contemporary, ASP-containing regimens. Ten of 54 (18.5%) consecutive adults developed symptomatic, objectively confirmed TE, at a median of 5.5 days after the first ASP dose. These were notable for CNS and upper extremity localization, varied significantly according to ALL immunophenotype (precursor B: 11% vs. T cell: 33%), without apparent effect of schedule or total dose of ASP. Median baseline AT level was 94% and fell to a nadir of 47% (P < 0.0001) during ASP therapy. Prophylactic AT had been given to 17 during ASP therapy. None of these developed TE vs. 10/37 (27%) without replacement (P = 0.021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions.

AB - Thromboembolism (TE) is a known complication of L-asparaginase (ASP) therapy of acute lymphoblastic leukemia (ALL), possibly attributable to reduced synthesis of natural anticoagulants, in particular antithrombin (AT). This retrospective single institution study was performed to determine the TE incidence among adults undergoing induction with contemporary, ASP-containing regimens. Ten of 54 (18.5%) consecutive adults developed symptomatic, objectively confirmed TE, at a median of 5.5 days after the first ASP dose. These were notable for CNS and upper extremity localization, varied significantly according to ALL immunophenotype (precursor B: 11% vs. T cell: 33%), without apparent effect of schedule or total dose of ASP. Median baseline AT level was 94% and fell to a nadir of 47% (P < 0.0001) during ASP therapy. Prophylactic AT had been given to 17 during ASP therapy. None of these developed TE vs. 10/37 (27%) without replacement (P = 0.021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions.

KW - Acute lymphoblastic leukemia

KW - Antithrombin

KW - L-asparaginase

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=3042777511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042777511&partnerID=8YFLogxK

U2 - 10.1080/10428190410001693588

DO - 10.1080/10428190410001693588

M3 - Article

VL - 45

SP - 1545

EP - 1551

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -